貴州百靈(002424.SZ)“一種治療胰島素抵抗的靶點及其應用”獲得專利申請受理通知書
格隆匯8月16日丨貴州百靈(002424.SZ)公佈,公司於2015年1月26日與香港大學簽訂了《合作研究合同》,公司委託香港大學研究開發“糖寧通絡膠囊治療糖尿病及併發症作用機理的研究”項目。
在研究過程中,基於新發現SBP2靶點和糖寧通絡原方及衍生物的研究結果,公司申請了“一種治療胰島素抵抗的靶點及其應用”的發明專利,公司近日收到國家知識產權局下發的《專利申請受理通知書》,發明創造名稱為一種治療胰島素抵抗的靶點及其應用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.